on SARTORIUS STED BIO (EPA:DIM)
Sartorius Stedim Biotech Releases 2025 Universal Registration Document
Sartorius Stedim Biotech SA has announced the availability of its 2025 Universal Registration Document. The document includes key information about the company's business development in 2025 and offers a forecast for 2026. It also features consolidated financial statements for the year ending December 31, 2025. Interested parties can access the document online through the company's investor relations webpage.
Sartorius Stedim Biotech, headquartered in Aubagne, France, is recognized as a major partner to the biopharmaceutical sector. The company provides innovative solutions for the safe, rapid, and sustainable production of biotech medications, including cell and gene therapies. In 2025, the company reported sales revenue of approximately 3 billion euros. Sartorius Stedim Biotech employs over 10,200 people globally and is listed on the Euronext Paris.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SARTORIUS STED BIO news